<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03231735</url>
  </required_header>
  <id_info>
    <org_study_id>F160701002</org_study_id>
    <nct_id>NCT03231735</nct_id>
  </id_info>
  <brief_title>Mid and Standard Frequency Ventilation in Infants With Respiratory Distress Syndrome</brief_title>
  <acronym>MIDAS</acronym>
  <official_title>A Randomized Controlled Trial of Mid and Standard Frequency Ventilation in Infants With Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine, in preterm infants less than 37 weeks gestation&#xD;
      with respiratory distress who are ventilated in the first 48 hours after birth, if mid&#xD;
      frequency ventilation strategy using ventilator rate of ≥ 60 to ≤ 150 per minute compared&#xD;
      with standard frequency ventilation strategy using ventilator rates of ≥ 20 to &lt; 60 per&#xD;
      minute will increase the number of alive ventilator-free days after randomization and reduce&#xD;
      the risk of ventilator induced lung injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In preterm infants with respiratory distress syndrome (RDS) who are ventilated in the first&#xD;
      48 hours after birth, mid frequency ventilation (MFV) strategy, compared with standard&#xD;
      frequency ventilation (SFV) strategy, in the first week after birth, will increase the number&#xD;
      of days alive and ventilator-free in the 28 days after birth.&#xD;
&#xD;
      This will be a randomized controlled trial with a 1:1 parallel allocation of infants to MFV&#xD;
      or SFV using stratified permuted block design. Randomization will be stratified by&#xD;
      gestational age (≥ 23 weeks to ˂ 26 weeks, ≥ 26 weeks to ≤ 28+6/7 (less than 29 weeks), and&#xD;
      29+0/7 to 36+6/7). Randomization of twins and higher orders (when eligible) will be to the&#xD;
      same group.&#xD;
&#xD;
      Inborn and outborn infants who are receiving assisted ventilation for RDS in the first 48&#xD;
      hours after birth will be included in this study. Infants with any of the following: a major&#xD;
      malformation, a neuromuscular condition that affects respiration, terminal illness or&#xD;
      decision to withhold or limit support will not be eligible.&#xD;
&#xD;
      Infants will be randomized to MFV versus SFV. MFV delivered at rates &gt; 60 per minute and ≤&#xD;
      150 per minute, with patient triggered ventilation and pressure support.&#xD;
&#xD;
      SFV delivered at rates &lt; 60 per minute and ≥ 20 per minute, with patient triggered&#xD;
      ventilation and pressure support.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a randomized controlled trial with a 1:1 parallel allocation of infants to mid or standard frequency ventilation using stratified permuted block design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alive ventilator free days</measure>
    <time_frame>Days 1-28 after birth</time_frame>
    <description>The number of days alive and ventilator-free</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alive at day 28 after birth</measure>
    <time_frame>Day 28 after birth</time_frame>
    <description>Number of infants alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free</measure>
    <time_frame>Day 28 after birth</time_frame>
    <description>Number of infants ventilator free</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia</measure>
    <time_frame>Measured at 36 weeks' postmenstrual age</time_frame>
    <description>Bronchopulmonary dysplasia in preterm infants less than 32 weeks' gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia</measure>
    <time_frame>Measured at 36 weeks' postmenstrual age</time_frame>
    <description>Bronchopulmonary dysplasia in preterm infants less than 29 weeks' gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Air leak syndrome</measure>
    <time_frame>Day 1-28 after birth</time_frame>
    <description>Rate of pulmonary interstitial emphysema and/or pneumothorax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary hemorrhage</measure>
    <time_frame>Day 1-28 after birth</time_frame>
    <description>Rate of pulmonary hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe (grade 3-4) intracranial hemorrhage</measure>
    <time_frame>Day 1-30 after birth</time_frame>
    <description>Rate of severe (grade 3-4) intracranial hemorrhage in infants less than 29 weeks' gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and continuous positive airway pressure/ventilator free</measure>
    <time_frame>Day 1-28 after birth</time_frame>
    <description>Number of days alive and ontinuous positive airway pressure/ventilator free</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and oxygen free</measure>
    <time_frame>Day 1-28 after birth</time_frame>
    <description>Number of days alive and oxygen free</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postnatal steroids</measure>
    <time_frame>Before 36 weeks' postmenstrual age</time_frame>
    <description>Rate of post natal steroids for bronchopulmonary dysplasia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis</measure>
    <time_frame>Days 1-120 after birth</time_frame>
    <description>Rate of proven necrotizing enterocolitis (NEC) in infants less than 29 weeks' gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental impairment</measure>
    <time_frame>18 to 24 months after birth</time_frame>
    <description>Rate of moderate to severe neurodevelopmental impairment in survivors &lt; 27 weeks' gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia or death</measure>
    <time_frame>Day 1-120 after birth</time_frame>
    <description>Rate of Bronchopulmonary dysplasia or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental impairment or death</measure>
    <time_frame>Day 1-120 after birth</time_frame>
    <description>Rate of Bronchopulmonary dysplasia or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia or death</measure>
    <time_frame>18 to 24 months after birth</time_frame>
    <description>Rate of moderate to severe neurodevelopmental impairment or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis or death</measure>
    <time_frame>Day 1-120 after birth</time_frame>
    <description>Rate of proven necrotizing enterocolitis or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Day 1-120 after birth</time_frame>
    <description>Death before hospital discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Ventilator-Induced Lung Injury</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <condition>Preterm Infant</condition>
  <arm_group>
    <arm_group_label>Mid frequency ventilation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mid frequency ventilation delivered at rates &gt; 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard frequency ventilation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard frequency ventilation delivered at rates &lt; 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mid frequency ventilation</intervention_name>
    <description>Mechanical ventilator used at rates &gt; 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.</description>
    <arm_group_label>Mid frequency ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard frequency ventilation</intervention_name>
    <description>Mechanical ventilator used at rates &lt; 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.</description>
    <arm_group_label>Standard frequency ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants ≥ 23+0/7 weeks and ≤ 36+6/7 who are intubated and mechanically ventilated for&#xD;
             respiratory distress syndrome (defined by use of surfactant) within 48 hours after&#xD;
             birth&#xD;
&#xD;
          -  Infants whose parents/legal guardians have provided consent for enrollment&#xD;
&#xD;
          -  Inborn or outborn infants transferred to this center before 48 hours after birth&#xD;
&#xD;
          -  Ventilator rate ≤ 80 per minute prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a major malformation, a neuromuscular condition that affects respiration, or terminal&#xD;
             illness or decision to withhold or limit support.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waldemar A Carlo, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colm P Travers, MD</last_name>
    <phone>2059344680</phone>
    <email>ctravers@peds.uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kalsang Dolma, MD</last_name>
    <phone>2059344680</phone>
    <email>kdolma@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colm P Travers, MD</last_name>
      <phone>205-934-4680</phone>
      <email>ctravers@peds.uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kalsang Dolma, MD</last_name>
      <phone>2059344680</phone>
      <email>kdolma@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Waldemar A Carlo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramachandra Bhat, MD</last_name>
      <phone>251-415-1000</phone>
      <email>rbhat@health.southalabama.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Colm Travers</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Ventilator-Induced Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

